Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours

Comparative Hepatology

Volumn 9, Issue , 2010, Pages

  van Sprundel, Renee G H M ^a   van den Ingh, Ted S G A M ^b   Desmet, Valeer J ^c   Katoonizadeh, Azeam ^c   Penning, Louis C ^a   Rothuizen, Jan ^a   Roskams, Tania ^c   Spee, Bart ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b TCCI Consultancy BV   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19; CYTOKERATIN 7; GLYPICAN 3; PROTEIN HEPPAR1; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; DISEASE MARKER; DISTANT METASTASIS; DOG; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; MALIGNANT TRANSFORMATION; NODULAR HYPERPLASIA; NONHUMAN; QUANTITATIVE STUDY; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION;

EID: 77949477712     PISSN: None     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-9-4     Document Type: Article

References (44)

1. Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP. Liver stem cells and hepatocellular carcinoma. Hepatology 2009, 49:318-329. 10.1002/hep.22704, 2726720, 19111019.
2. Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis 2003, 23:385-396. 10.1055/s-2004-815564, 14722815.
3. Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J. Expected developments in hepatology. Best Pract Res Clin Gastroenterol 2002, 16:957-970. 10.1053/bega.2002.0341, 12473301.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156. 10.1002/ijc.1440, 11668491.
5. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998, 28:1241-1246. 10.1002/hep.510280511, 9794907.
6. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003, 38:200-207. 10.1016/S0168-8278(02)00360-4, 12547409.
7. Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M. Recurrence of hepatocellular carcinoma after surgery. Br J Surg 1996, 83:1219-1222. 10.1002/bjs.1800830913, 8983610.
8. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF. Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg 2006, 93:600-606. 10.1002/bjs.5335, 16607679.
9. Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med 1989, 113:134-138.
10. Van Eyken PL, Sciot R, Van Damme B, De Wolf-Peeters C, Desmet VJ. Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol 1987, 412:63-72. 10.1007/BF00750732, 2446418.
11. Roskams T, De Vos R, van Eyken P, Myazaki H, Van Damme B, Desmet V. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 1998, 29:455-463. 10.1016/S0168-8278(98)80065-2, 9764994.
12. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, Lesaffre E, Libbrecht L, Desmet V, Roskams T. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006, 49:138-151. 10.1111/j.1365-2559.2006.02468.x, 16879391.
13. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, Tanaka S, Kaneda K, Hirohashi K. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003, 94:851-857. 10.1111/j.1349-7006.2003.tb01366.x, 14556657.
14. van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 1988, 19:562-568. 10.1016/S0046-8177(88)80205-3, 2453442.
15. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol 1996, 149:1167-1175. 1865193, 8863666.
16. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: A systematic review. Eur J Cancer 2007,
17. Nagao T, Inoue S, Yoshimi F, Sodeyama M, Omori Y, Mizuta T, Kawano N, Morioka Y. Postoperative recurrence of hepatocellular carcinoma. Ann Surg 1990, 211:28-33. 10.1097/00000658-199001000-00005, 1357889, 1688488.
18. Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006, 243:229-235. 10.1097/01.sla.0000197706.21803.a1, 1448919, 16432356.
19. Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 2006, 86:1272-1284. 10.1038/labinvest.3700479, 17117158.
20. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa CA, Rullier A, Cubel G, Couchy G, Imbeaud S, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46:740-748. 10.1002/hep.21743, 17663417.
21. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terracciano L, Tornillo L, Vecchione R, Roncalli M. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007, 45:725-734. 10.1002/hep.21531, 17326147.
22. Neff MW, Rine J. A fetching model organism. Cell 2006, 124:229-231. 10.1016/j.cell.2006.01.008, 16439192.
23. Libbrecht L. Hepatic progenitor cells in human liver tumor development. World J Gastroenterol 2006, 12:6261-6265.
24. Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002, 13:419-424. 10.1016/S1084952102001295, 12468242.
25. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, Roberts LR, Demetris AJ, Sun Z, Nevens F, Roskams T, Thorgeirsson SS. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006, 12:410-416. 10.1038/nm1377, 16532004.
26. Oh BK, Kim H, Park YN, Yoo JE, Choi J, Kim KS, Lee JJ, Park C. High telomerase activity and long telomeres in advanced hepatocellular carcinomas with poor prognosis. Lab Invest 2008, 88:144-152. 10.1038/labinvest.3700710, 18158557.
27. Sell S. The role of determined stem-cells in the cellular lineage of hepatocellular carcinoma. Int J Dev Biol 1993, 37:189-201.
28. Libbrecht L, Severi T, Cassiman D, Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006, 30:1405-1411. 10.1097/01.pas.0000213323.97294.9a, 17063081.
29. Kitao S, Yamada T, Ishikawa T, Madarame H, Furuichi M, Neo S, Tsuchiya R, Kobayashi K. Alpha-fetoprotein in serum and tumor tissues in dogs with hepatocellular carcinoma. J Vet Diagn Invest 2006, 18:291-295.
30. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001, 35:421-430. 10.1016/S0168-8278(01)00130-1, 11592607.
31. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004, 3:73-81.
32. Dobashi N, Fujita J, Murota M, Ohtsuki Y, Bandoh S, Ueda Y, Dohmoto K, Hojo S, Nishioka M, Ishida T, Takahara J. Binding of recombinant human cytokeratin 19 to laminin: a possible role in interaction between intermediate filament derived from epithelial cells and extracellular matrixes. Cell Struct Funct 2000, 25:171-175. 10.1247/csf.25.171, 10984100.
33. Chu YW, Runyan RB, Oshima RG, Hendrix MJ. Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 1993, 90:4261-4265. 10.1073/pnas.90.9.4261, 46486, 7683431.
34. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T, Nishiguchi S. Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 2003, 88:1894-1899. 10.1038/sj.bjc.6601026, 2741125, 12799633.
35. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T, Takahara J. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. Int J Cancer 2001, 91:468-473. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1082>3.0.CO;2-T, 11251967.
36. Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y, Kuriyama S. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. Int J Oncol 2002, 21:441-445.
37. Iyer A, Robert ME, Bifulco CB, Salem RR, Jain D. Different cytokeratin and neuronal cell adhesion molecule staining patterns in focal nodular hyperplasia and hepatic adenoma and their significance. Hum Pathol 2008, 39:1370-1377. 10.1016/j.humpath.2008.01.015, 18602664.
38. Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008, 21:1011-1018. 10.1038/modpathol.2008.85, 18536657.
39. Sung YK, Hwang SY, Park MK, Farooq M, Han IS, Bae HI, Kim JC, Kim M. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003, 94:259-262. 10.1111/j.1349-7006.2003.tb01430.x, 12824919.
40. Vauthey JN, Lauwers GY. Prognostic factors after resection of hepatocellular carcinoma: are there landmarks in the wild forest?. J Hepatol 2003, 38:237-239. 10.1016/S0168-8278(02)00407-5, 12547414.
41. Patnaik AK, Newman SJ, Scase T, Erlandson RA, Antonescu C, Craft D, Bergman PJ. Canine hepatic neuroendocrine carcinoma: an immunohistochemical and electron microscopic study. Vet Pathol 2005, 42:140-146. 10.1354/vp.42-2-140, 15753467.
42. Trigo FJ, Thompson H, Breeze RG, Nash AS. The pathology of liver tumours in the dog. J Comp Pathol 1982, 92:21-39. 10.1016/0021-9975(82)90040-8, 6279705.
43. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43:515-524. 10.1002/hep.21068, 16496320.
44. Komuta M, Spee B, Borght S, De Vos R, Verslype C, Aerts R, Yano H, Suzuki T, Matsuda M, Fujii H, Desmet VJ, Kojiro M, Roskams T. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008, 47:1544-1556. 10.1002/hep.22238, 18393293.